Looking for something specific?
At 9M India Limited, trust through quality, transparency, performance.
WHAT WE MANUFACTURE

Nutritional deficiency is a major health burden across India and export markets. Syrup formats are preferred for paediatric and maternal supplementation due to ease of swallowing and dose titration. Our nutritional syrup range:
WHY 9M INDIA
Nutritional syrups containing Iron require specific formulation expertise — Iron syrups can stain teeth, cause GI upset and oxidise if incorrectly formulated. 9M India's Iron syrup formulations use validated antioxidant systems, appropriate pH control and either standard Ferrous Sulphate, Ferrous Ascorbate or Iron Polymaltose Complex APIs to deliver different tolerance and stability profiles depending on the requirement.
Clarity and colour · pH · Assay of all active components by HPLC/AAS · Microbial limits · Fill volume · Viscosity · Iron content verification · Vitamin stability — all in-house. COA per batch.
Manufacturing Licence · DCGI product approvals · WHO-GMP Certificate · COA · COC · Stability data — pre-prepared and available within 24 hours for tender submission, export registration or contract manufacturing due diligence.
WHO WE SUPPLY
Government & institutional buyers
Government Anaemia Mukt Bharat programme, ICDS, NHM maternal health — Iron + Folic Acid syrup is one of the single highest-volume nutritional supplements procured by government programmes.
Private label & contract manufacturing partners
Domestic maternal and paediatric nutrition brands manufacturing through 9M India — the Indian haematinic syrup market exceeds ₹2,000 Cr annually.
International export buyers
African buyers specifically — anaemia burden is high across Sub-Saharan Africa and Iron + Folic Acid syrups, Zinc syrups and Multivitamin syrups are among the most requested products from our African distribution partners.
EXPORT MARKETS & Nutritional Haematinic
9M India exports antidiabetic capsules to 15+ countries across Phase 1 export markets including the UAE, Egypt, Iraq, Mexico, Russia, Kazakhstan, Sri Lanka and others in the Middle East, CIS, Africa and ASEAN. Diabetes prevalence is highest in exactly the markets we serve — making antidiabetic formulations one of our highest-demand export categories.
WHO-GMP Certificate
DCGI Manufacturing Licence
Certificate of Pharmaceutical Product (CoPP)
Certificate of Analysis (CoA) — batch-wise
CTD / ACTD Dossier — on request
Stability Data — ICH Zone IVb (30°C/75% RH)
Share your molecule, formulation, pack size and target market. We confirm capability, documentation and lead times within 24 hours.
WHO-GMP
Certified
1,000+
Formulations
15+ Countries
Supplied
DCGI
Approved
Therapeutic Categories
We keep answer short
01
9M India manufactures antidiabetic capsules across all major pharmacological classes including Biguanides (Metformin), Sulphonylureas (Glibenclamide, Glimepiride, Gliclazide), SGLT2 inhibitors (Dapagliflozin), DPP-4 inhibitors (Sitagliptin, Linagliptin) and fixed-dose combination formulations. All are manufactured at our WHO-GMP certified facility in Birkoni, Chhattisgarh.
02
Yes. 9M India manufactures Metformin Hydrochloride in both immediate-release (500mg, 850mg) and extended-release / sustained-release (500mg, 1000mg) formats. Extended-release Metformin is associated with better gastrointestinal tolerability and is increasingly preferred in clinical practice
03
Yes. 9M India manufactures several fixed-dose combination antidiabetic formulations including Metformin + Glibenclamide, Metformin + Glimepiride, Metformin + Sitagliptin and Metformin + Gliclazide SR. These combination capsules improve compliance in Type 2 diabetes management and are in strong demand across export markets.
04
Yes. 9M India is equipped to supply antidiabetic medicines for national diabetes control programmes and institutional procurement. We support large-volume orders with flexible packaging, complete GMP documentation, CoPP, batch CoA and tender compliance support.
05
9M India exports antidiabetic capsules to Phase 1 markets including the UAE, Egypt, Iraq, Mexico, Russia, Kazakhstan and others across the Middle East, CIS, Africa and ASEAN. Diabetes prevalence is highest in these regions, making antidiabetics a consistently high-volume export category for us.